PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 19 | 4 |

Tytuł artykułu

Lithium and the application of its compounds in different fields of medicine

Treść / Zawartość

Warianty tytułu

PL
Lit i zastosowanie związków tego pierwiastka w różnych dziedzinach medycyny

Języki publikacji

EN

Abstrakty

EN
Although lithium has not been classified as an essential element for humans, it can influence numerous metabolic processes and exert diverse effects in the human body, both positive and negative ones. Its actions enable the use of lithium compounds in therapy of different illnesses. It is mostly used for cure of psychiatric disorders: as a mood stabilizer and for intensifying the action of antidepressants. However, its compounds have been also tried in other fields of medicine: as an adjuvant in patients with thyroid diseases undergoing radioiodine therapy, in dermatology, in cure of neurodegenerative and ophthalmic illnesses as well as in tumour therapy. Lithium displays beneficial action only within a determined range of its serum concentration and an overrun of the safe threshold can cause side effects. Due to this fact, the Li serum level as well as many other factors, e.g.: body weight, creatinine, renal and thyroid functions should be monitored during the whole therapy. Many studies were undertaken to clarify the mechanism by which lithium affects organisms but the results still remain unsatisfactory. Nevertheless, some interesting aspects of lithium action have been revealed, including its effect on the enzymatic activity, neurodegenerative processes, apoptosis, formation of cytokines as well as neurotransmission and oxidant balance.
PL
Obecność litu w organizmie może wywierać różnorodny wpływ zarówno korzystny, jak i negatywny na liczne procesy metaboliczne, jednakże nie został on jeszcze zaliczony do pierwiastków niezbędnych dla człowieka. Działanie litu umożliwiło zastosowanie jego związków w terapii różnych chorób. Jest on głównie stosowany w przypadkach zaburzeń psychicznych jako stabilizator nastroju oraz środek potencjalizujący działanie leków przeciwdepresyjnych. Przeprowadzono również próby zastosowania jego związków w innych dziedzinach medycyny: do wspomagania terapii radiojodem stosowanej w chorobach tarczycy, w dermatologii, w leczeniu schorzeń neurodegeneracyjnych i chorób oczu oraz w leczeniu nowotworów. Lit wywiera działanie terapeutyczne jedynie wtedy, gdy jego stężenie w surowicy mieści się w określonym zakresie, a przekroczenie dopuszczalnej wartości może spowodować działania uboczne. Z tego powodu stężenie litu w surowicy, podobnie jak wiele innych czynników, takich jak: masa ciała, poziom kreatyniny oraz funkcje tarczycy i nerek, musi być monitorowane podczas całej terapii. W celu wyjaśnienia mechanizmu oddziaływania litu na organizm przeprowadzono wiele badań, ale rezultaty są wciąż niezadowalające, niemniej jednak odkryto liczne, interesujące aspekty działania litu, m.in. wpływ na aktywność enzymatyczną, procesy neurodegeneracyjne i neurotransmisyjne, apoptozę, produkcję cytokin oraz na procesy pro- i antyoksydacyjne.

Słowa kluczowe

Wydawca

-

Rocznik

Tom

19

Numer

4

Opis fizyczny

p.1167-1178,ref.

Twórcy

  • Chair and Department of Medical Chemistry, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland
autor
  • Chair and Department of Medical Chemistry, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland

Bibliografia

  • Agam G., Sham ir A., Shaltiel G., Greenberg M.L. 2002. Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord., 4(Suppl 1): 15-20.
  • Aghdam S.Y., Barger S.W. 2007. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr. Alzheimer Res., 4: 21-31.
  • Al-Azemi M., Omu F.E., Kehinde E.O., Anim J.T., Oriowo M.A., Omu A.E. 2010. Lithium protects against toxic effects of cadmium in the rat testes. J. Assist. Reprod. Genet., 27: 469-476.
  • Aral H., Vecchio-Sadus A. 2008. Toxicity of lithium to humans and the environment - A literature review. Ecotoxicol. Environ. Saf., 70: 349-356.
  • Assadi M., Janson C., Wang D.J., Goldfarb O., Suri N., Bilaniuk L., Leone P. 2010. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur. J. Pediatr. Neurol., 14: 354-359.
  • Bal C.S., Kumar A., Pandey R.M. 2002. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 12: 399-405.
  • Beręsewicz M. 2000. Lithium carbonate as a substance potentiating the effect antidepressants in drug-resistant depressions. Farmakot. Psychiatr. Neurol., 1: 40-48. (in Polish)
  • Berry G.T., Buccafusca R., Greer J.J., Eccleston E. 2004. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Mol. Genet. Metab., 82: 87-92.
  • Bhalla P., Dhawa n D.K. 2009. Protective role of lithium in ameliorating the aluminium-induced oxidative stress and histological changes in rat brain. Cell. Mol. Neurobiol., 29: 513-521.
  • Bielecka A.M., Obuchowicz E. 2008. Antiapoptotic action of lithium and valproate. Pharmacol. Reports, 60: 771-782.
  • Birkenhäger T.K., Van Den Broek W.W., Fekkes D., Mulder P.G., Molema n P., Bruijn J.A. 2007. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31: 1084-1088.
  • Bogazz i F., Giova nnetti C., Fess ehatsion R., Tanda M.L., Campomori A., Compri E., Rossi G., Ceccarelli C., Vitti P., Pinchera A., Bartalena L., Martino E. 2010. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time of cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J. Clin. Endocrinol. Metab., 95: 201-208.
  • Brandish P.E., Su M., Holder D.J., Hodor P., Szumiloski J., Kleinhanz R.R., Forbes J.E., Mcwhorter M.E., Duewa ld S.J., Parrish M.L., Na S., Liu Y., Phillips R.L., Renger J.J., Sanakranarayanan S., Simon A.J., Scolnick E.M. 2005. Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron, 45: 861-872.
  • Camins A., Verdag uer E., Junyent F., Yeste-Velas co M., Pelegrí C., Vilap lana J., Pallás M. 2009. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci. Ther., 15: 333–344.
  • Chiu C.C., Shen W.W., Chen K.P, Lu M.L. 2007. Application of the Cockroft-Gault method to estimate lithium dosage requirement. Psychiatry Clin. Neurosci, 61: 269-274.
  • Chiu C.-T., Chuang D.-M. 2010. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther., 128: 281-304.
  • Chmielnicka J., Nasiadek M. 2003. The trace elements in response to lithium intoxication in renal failure. Ecotoxicol. Environ. Saf., 55: 178-183.
  • Collins N., Barnes T.R.E., Shingleton-Smith A., Gerrett D., Paton C. 2010. Standards of lithium monitoring in mental health trusts in the UK. BMC Psychiatry, 10: 80-86.
  • Constantinou C., Bolaris S., Valcana T., Marga rity M. 2005. Acute LiCl-treatment affects the cytoplasmic T4 availability and the expression pattern of thyroid hormone receptors in adult rat cerebral hemispheres. Neurosci. Res., 51: 235-241.
  • De Almeida Souza A., Da Silva G.S.S., Velez B.S., Santoro A.B.M., Montero-Lomelí M. 2010. Glycogen synthesis in brain and astrocytes is inhibited by chronic lithium treatment. Neurosci. Lett., 482: 128-132.
  • Dou H., Ellison B., Bradley J., Kasiyanov A., Poluectova L.Y., Xiong H., Maggirwa r S., Dewhurst S., Gelbard H.A., Gendelma n H.E. 2005. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J. Neurosci., 25: 8375-8385.
  • Duffy A., Alda M., Kutcher S., Cavazzoni P., Robertson C., Grof E., Grof P. 2002. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J. Clin. Psychiatry, 63: 1171-1178.
  • Dunn N., Holmes C., Mullee M. 2005. Does lithium therapy protect against the onset of dementia? Alzheimer Dis. Assoc. Disord., 19: 20-22.
  • Engin A., Altan N., Isik E. 2005. Erythrocyte glutathione levels in lithium-induced hypothyroidism. Drugs R D., 6: 35-40.
  • Feyt C., Kienlen-Campard P., Leroy K., N’kuli F., Courtoy P.J., Brion J.P., Octav e J.N. 2005. Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J. Biol. Chem., 280: 33220-33227.
  • Galbally M., Roberts M., Buist A.; Perinatal Psychotropic Review Group. 2010. Mood stabilizers in pregnancy: a systematic review. Aust. N. Z. J. Psychiatry, 44: 967-77.
  • Gentile S. 2011. Drug treatment for mood disorders in pregnancy. Curr. Opin. Psychiatry, 24: 34-40.
  • Georgotas A., Gershon S. 1981. Historical perspectives and current highlights on lithium treatment in manic-depressive illness. J. Clin. Psychopharmacol., 1: 27-31.
  • Gould T.D., Manji H.K. 2005. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology, 30: 1223-1237.
  • Hanson N.D., Nemeroff C.B., Owens M.J. 2011. Lithium, but not fluoxetine or the corticotropin -releasing factor receptor 1 receptor antagonist r121919, increases cell proliferation in the adult dentate gyrus. J. Pharmacol. Exp. Ther., 337: 180-186.
  • Howland R.H. 2009. Prescribing psychotropic medications during pregnancy and lactation: principles and guidelines. J. Psychosoc. Nurs. Ment. Health Serv., 47: 19-23.
  • Huang X., Wu D.Y., Chen G., Manji H., Chen D.F. 2003. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest. Ophthalmol. Vis. Sci., 44: 347-354.
  • Huang X., Lei Z., El-Mallakh R.S. 2007. Lithium normalizes elevated intracellular sodium. Bipolar Disord., 9: 298–300.
  • Hwang G.S., Yang J.Y., Ryu Do H., Kwon T.H. 2010. Metabolic profiling of kidney and urine in rats with lithium-induced nephrogenic diabetes insipidus by (1)H-NMR-based metabonomics. Am. J. Physiol. Renal. Physiol., 298: F461-F470.
  • Janson C.G., Assadi M., Francis J., Bilaniuk L., Shera D., Leone P. 2005. Lithium citrate for Canavan disease. Pediatr. Neurol., 33: 235-243.
  • Johnson C.D., Puntis M., Dav idson N., Todd S., Bryce R. 2001. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br. J. Surg., 88: 662-668.
  • Kessing L.V., Søndergård L., Forman J.L., Andersen P.K. 2008. Lithium treatment and risk of dementia. Arch. Gen. Psychiatry, 65: 1331-1335.
  • Kliwicki S., Rybakowski J. 2009. Fourty six years of lithium salt in prevention of recurrences of bipolar affective illness. Farmakoter. Psychiatr. Neurol. 25: 167-172. (in Polish)
  • Knijff E.M., Breunis M.N., Kupka R.W., De Wit H.J., Ruwhof C., Akkerhuis G.W., Nolen W.A., Drexhag e H.A. 2007. An imbalance in the production of IL-1β and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord., 9: 743-753.
  • Leroy A., Landrieu I., Huvent I., Legrand D., Codeville B., Wierusz eski J.M., Lipp ens G. 2010. Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. Biol. Chem., 285: 33435-33444. Levine S., Saltzma n A. 2006. Lithium increases body weight of rats: Relation to thymolisis. Prog. Neropsycholpharmacol. Biol. Psychiatry, 30: 155-158.
  • Li Q., Li H., Roughton K., Wang X., Kroemer G., Blomg ren K., Zhu C. 2010. Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell Death Dis., 1: e56.
  • Liu Y.Y., Van Der Pluijm G., Karperien M., Stokkel M.P.M., Pereira A.M., Morreau J., Kievit J., Romijn J.A., Smit J.W.A. 2006. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin. Endocrinol. (Oxf), 64: 617-624.
  • Luo J. 2010. Lithium-mediated protection against ethanol neurotoxicity. Front. Neurosci., 4: 41.
  • Mišak A. 2005. Instability of Carbolith (lithium carbonate). CMAJ, 172: 183.
  • Möller H.J. 2003. Bipolar disorder and schizophrenia: distinct illnesses or a continuum? J. Clin. Psychiatry, 64(Suppl 6): 23-27.
  • Nakashima H., Ishikara T., Suguimoto P., Yokota O., Oshima E., Kugo A., Terada S., Hamam ura T., Trojanowski J.Q., Lee V.M., Kuroda S. 2005. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol., 110: 547-556.
  • Nciri R., Allag ui M., Vincent C., Murat J.C., Croute F., El Feki A. 2009. The effects of subchronic lithium administration in male Wistar mice on some biochemical parameters. Hum. Exp. Toxicol., 28: 641-646.
  • Ng Y.W., Tiu S.C., Choi K.L., Chan F.K.W., Choi C.H., Kong P.S., Ng C.M., Shek C.C. 2006. Use of lithium in the treatment of thyrotoxicosis. Hong Kong Med. J., 12: 254-259.
  • Nguyen T.T., Sharma V., Mcintyre R.S. 2009. Teratogenesis associated with antibipolar agents. Adv. Ther., 26: 281-94.
  • O’donnell T., Rotzinger S., Ulrich M., Hanstock C.C., Nakas hima T.T., Silverstone P.H. 2003. Effect of chronic lithium and sodium valproate on concentrations of brain amino acids. Eur. Neuropsychopharmacol., 13: 220-227.
  • Olszewska K., Rybakowski J. 2007. Influence of antypsychotic medications on carbohydrate and lipid metabolism in schizophrenia and bipolar affective illness. Psychiatria, 4: 8-16. (in Polish)
  • Oszukowska L., Knapska-Kucharska M., Makarewicz J., Lewiński A. 2010. The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment (131I) in hyperthyroid patients. Pol. J. Endocrinol., 61: 56-61.
  • Ovsepian L.M., Kazarian G.V., Zakharian A.V., Zakharian G.V., L’vov M.V. 2010. Effect of cystheine lithium salt on lipid peroxidation in the model of dopaminergic system disorder. Eksp. Klin. Farmakol., 73: 16-18. (in Russian)
  • Ozsoy S., Mavili E., Aydιn M., Turan T., Esel E. 2010. Ultrasonically determined thyroid volume and thyroid functions in lithium-naïve and lithium-treated patients with bipolar disorder: a cross-sectional and longitudinal study. Hum. Psychopharmacol. Clin. Exp., 25: 174-178.
  • Permoda-Osip A., Rybakowski J. 2009. Biological mechanisms of lithium action in the context of mood-stabilizing effect. Farmakoter. Psychiatr. Neurol., 25: 7-15. (in Polish)
  • Pietruczuk K., Witkowski J.M. 2008. Lithium salts - mechanisms of action. Psychiatria, 5: 51-57. (in Polish)
  • Rachimi Balaei M., Momeny M., Babaeikelishomi R., Ejtemaei Mehr S., Tavangar Sm., Dehpour A.R. 2010. The modulatory effect of lithium on doxorubicin-induced cardiotoxity in rat. Eur. J. Pharmacol., 641: 193-198.
  • Rapoport S.I., Bosetti F. 2002. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry, 59: 592-596.
  • Remlinger-Molenda A., Rybakowski J. 2010 Neuroimmunology of bipolar affective disorder. Psychiatr. Pol., 44: 27-38. (in Polish)
  • Rybakowski J. 2010. Progress in diagnostics and therapy of depression an bipolar affective illness. Prz. Lek., 34: 125-130. (in Polish)
  • Rybakowski J.K., Suwalska A. 2010. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int. J. Neuropsychopharmacol., 13: 617-622.
  • Scheuch K., Höltje M., Budde H., Lautenschlag er M., Heinz A., Ahnert-Hilger G., Priller J. 2010. Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons. Brain Res., 1307: 14-21.
  • Shao L., Young L.T. Wang J.F. 2005. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat celebral cortical cells. Biol. Psychiatry, 58: 879-884.
  • Martins L.F., Montero-Lomelí M., Mas uda C.A., Fortes F.S., Previato J.O., Mendonça-Previato L. 2008. Lithium-mediated suppression of morphogenesis and growth in Candida albicans. FEMS Yeast Res., 8: 615-621.
  • Maurer I.C., Schipp el P., Volz H.-P. 2009. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord., 11: 515-522.
  • Medhi B., Prakas h O., Jose V.M., Pradhan B., Chakrabarty S., Pandhi P. 2008. Seasonal variation in plasma levels of lithium in the Indian population: is there a need to modify the dose? Singapore Med. J. 49: 724-727.
  • Sharma S.D., Iqbal M. 2005. Lithium induced toxicity in rats: a hematological, biochemical and histopathological study. Biol. Pharm. Bull., 28: 834-837.
  • Sparsa A., Bonnetblanc J.M. 2004. Lithium. Ann. Dermatol. Venereol., 131: 255-261. (in French)
  • Strzelecki D. 2006. Endocrine and metabolic side-effects of lithium. Farmakoter. Psychiatr. Neurol. 22: 159-166. (in Polish)
  • Szczepankiewicz A., Skibińska M., Suwalska A., Hauser J., Rybakowski J.K. 2009. No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacol. Reports, 61: 448-452.
  • Vannucchi G., Chiti A., Mannav ola D., Dazz i D., Rodari M., Tadayyon S., Beck-Peccoz P., Fugaz -zola L. 2005. Radioiodine treatment of non-toxic multinodular goitre: effects of combination with lithium. Eur. J. Nucl. Med. Mol. Imaging , 32: 1081-1088.
  • Vijaimohan K., Mallika J., Shyamala D.C.J. 2010. Chemoprotective effect of sobatum against lithium-induced oxidative damage in rats. J. Young Pharm., 2: 68-73.
  • Wegener G., Bandpey Z., Heiberg I.L. Volke V., Trabace L., Rosenberg R., Harvey B.H. 2004. Combined chronic treatment with citalopram and lithium does not modify the regional neurochemistry of nitric oxide in rat brain. J. Physiol. Pharmacol., 55: 575-586.
  • Wiernsperger N., Rap in J.R. 2010. Trace elements in glucometabolic disorders: an update. Diabetol. Metab. Syndr., 2: 70-78.
  • Wilkowska A., Ściepuro A., Kujawska H., Sein A.J. 2006 Chronic iatrogenic lithium intoxication complicated by bradycardia: a case report. Pol. Arch. Med. Wewn., 116: 1068-1071. (in Polish)
  • Wilting I., Fase S., Martens E.P., Heerdink E.R., Nolen W.A., Egberts A.C.G. 2007. The impact of environmental temperature on lithium serum levels. Bipolar Disord., 9: 603-608.
  • Woźniak M. 2008 Lithium, a forgotten medicament. Terapia, 16: 44-46. (in Polish)
  • Zarse K., Terao T., Tian J., Iwata N., Ishii N., Ristow M. 2011. Low-dose lithium uptake promotes longevity in humans and metazoans. Eur. J. Nutr., 50: 387-389.
  • Zhang A., Huang X., Luo P., Jiang X. 1998. Study of inhibition and prevention of tumor and antioxidative effects of lithium carbonate in tumor bearing mice. Wei Sheng Yan Jiu, 27: 77-80. (in Chinese)
  • Zhong J., Lee W.H. 2007. Lithium: a novel treatment for Alzheimer’s disease? Expert Opin. Drug Saf., 6: 375-383.

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.agro-9d308ad7-4a60-46db-b551-0294537bf1ae
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.